Contact: Maureen Murphy BirthNet, 518-465-5087
Gaskin to Speak about Ulcer Drug Used on Pregnant Women to Induce Labor
Ina May Gaskin, Certified Professional Midwife (CPM) and President of the Midwives Alliance
of North America (MANA), will be the keynote speaker at the MANA North Atlantic Regional
Conference on June 9, 2001 at Camp Deer Park near Port Jervis, New York. Gaskin’s workshop,
entitled “Routes of Induction and the Cytotec Dilemma,” will describe the use of the stomach-
ulcer drug, Cytotec, for labor induction and why this practice should end.
Cytotec (generic name misoprostol) is an ulcer medication that is being used by doctors and
midwives across the country to induce labor in pregnant women. Cytotec is taken orally or
inserted vaginally to soften the cervix and cause uterine contractions that are stronger and more
frequent than normal labor. Gaskin contends that the use of Cytotec for labor induction has
become a massive medical experiment involving thousands of unsuspecting and uninformed
Cytotec has become popular because of its cost and ease of its use. A 25mcg dose costs about 13
cents, while most other labor inducing drugs cost hundreds of dollars. Although induction is
only medically necessary if the mother is overdue or at risk due to diabetes or high blood
pressure, the use of Cytotec contributes to the increase in medically unnecessary inductions. The
induction rate in this country has doubled in the last ten years to 17% or nearly 1 in 5 women.
The Food and Drug Administration (FDA) has notapproved Cytotec for induction and has
warned against its use for this purpose. The agency has received reports of 30 cases of uterine
rupture and eight cases in which the baby died during Cytotec inductions over the past three
years. In addition, the manufacturer of the drug, G.D. Searle Corporation, has inserted a warning
into each package of Cytotec cautioning that Cytotec may cause uterine rupture, severe bleeding,
Educating the public to improve ma ternity care for all women
The American College of Obstetricians and Gynecologists does not recommend Cytotec’s use
for women who have had previous cesareans due to a high risk of uterine rupture. The Cochrane
Collaboration, an international organization that conducts up-to-date reviews of healthcare
studies, has concluded that further research is necessary because of concerns about dosage and
BirthNet is seeking to educate the public about Cytotec, so women can make informed decisions
about their care. A survey of Capital District hospitals found that, out of eight hospitals surveyed
in the area, three use Cytotec for labor induction, four do not, and one had no comment. One of
the four, Albany Medical Center, discontinued its use after Searle’s warning was published.
Ina May Gaskin will be speaking about Cytotec at the MANA regional conference at Camp Deer
Park in Westbrookville, New York on June 9, 2001, at 9:15 am. Contact Susan Rannestad at
845-744-5534 for conference information or Ina May Gaskin at 1-888-923-MANA (6262) or at
BirthNet educates the public about maternity care in order to improve it. We believe that birth is
a normal, natural event in a woman's life; and we encourage women to learn about their rights
and options. Our primary programs include education in the classroom (high school or college
classes), community forums or workshops, and media outreach. For more information, please
Educating the public to improve ma ternity care for all women
Publications for which Dr. Novack was the medical writer Dell SJ, Hovanesian JA, Raizman MB, et al. Randomized comparison of postoperative use of hydrogel ocular bandage and collagen corneal shield for wound protection and patient tolerability after cataract surgery. J Cataract Refract Surg 2011;37:113-21. Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent
Pregnancy & Breastfeeding – Safe Use of Anti‐infective Agents ANTIBACTERIAL AGENTS Name of Agent / Class Pregnancy Breastfeeding Aminoglycosides Amikacin • Not expected to increase risk of major congenital • Considered safe during breastfeeding • Monitor nursing infant for GI symptoms. • Monitor drug concentrations for efficacy as higher •